DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapy solutions for food allergies and other immunological conditions. Utilizing its proprietary Viaskin® technology, DBV Technologies aims to transform the management of food allergies by delivering allergen-specific treatments through epicutaneous immunotherapy. The company’s research and development pipeline targets unmet medical needs, with a primary emphasis on pediatric and adolescent populations. DBV Technologies collaborates with healthcare professionals, researchers, and regulatory authorities to advance safe and effective therapies. Committed to scientific excellence and patient well-being, DBV Technologies strives to set new standards in allergy treatment and immunotherapy, supporting improved quality of life for patients worldwide.
